Pharma Market Access Insights - from Petauri Evidence

Send us Fan Mail
How will Most Favored Nation (MFN) pricing reshape global pharmaceutical strategy? What do emerging Centers for Medicare & Medicaid Service (CMS) models such as GENEROUS, GLOBE, and GUARD mean for launch planning, pricing corridors, and payer expectations worldwide? How should global market access teams prepare for a more transparent and tightly connected pricing environment?
MFN reform is already influencing how companies plan, price, and launch medicines around the world. While CMS proposals sit at the center of the debate, the implications extend far beyond the US. The increased transparency required in models under consideration has the potential to accelerate global price convergence, affect international reference dynamics, and place new pressures on evidence generation, launch sequencing, and global pricing corridors.
This episode was first broadcast as a live webinar on Wednesday 15th April 2026. It is designed to help global and US teams understand and anticipate the worldwide strategic implications of MFN policy. 
The session brought together four experts offering global and US perspectives on MFN:
Steve O’Malley (President, Petauri Advisors): Moderator and contributor on US access and strategic implications
Catherine Beecher (Director – Global Pricing and Market Access, Petauri Evidence): Bringing insight into global evidence requirements, lifecycle planning, and cross‑market pricing pressures
Clare Foy (Director – Global Pricing and Market Access, Petauri Evidence): Bringing expertise in global pricing strategy and launch planning across international markets
Michael Garner (Vice President, Artia Solutions – Powered by Petauri): Bringing US Medicaid expertise with a focus on CMS MFN proposals and their operational and strategic implications
Learn more at: https://petauri.com/insights/global-market-access-strategy-for-mfn/
In this webinar, we explored:
The most recent CMS MFN policy developments and how models such as GENEROUS, GLOBE, and GUARD may evolve
The possible effects of the recent announcement of new tariffs on pharmaceutical manufacturers
How greater price transparency could affect international pricing corridors and global revenue forecasts
Impacts on launched products, peri-launch assets, and early pipeline programs from both a global and US policy standpoint
Strategic options for optimizing ex-US price potential, including evidence generation, innovative agreements, conditional reimbursement, and launch sequencing
How global market access teams can build pricing and access strategies that remain resilient as MFN models evolve
Wider policy developments to monitor outside the US, including proposed changes to the exclusivity period in the EU, and the growing influence of the Joint Clinical Assessment
Learn more about our pricing and market access strategy services.
Subscribe to our newsletter to hear more  news, insights and events from Petauri Evidence

Send us Fan Mail
How do LATAM healthcare markets differ and what do these differences mean for Pharma and Medtech launch planning? What should global market access teams know to support affiliates in Argentina, Brazil, Colombia, and Mexico? How do evidence requirements, access routes, and payer expectations vary across the region?

For global market access teams planning for launch in Latin America (LATAM), understanding the diversity and complexity of this region is essential. Healthcare systems vary significantly between markets, regulatory and payer expectations differ, and health technology assessment (HTA) processes continue to evolve. These differences create both opportunities and challenges for Pharma and Medtech companies preparing evidence, developing global plans, and equipping local affiliates with the right materials to secure access.

In this episode, Louise Maddison (Senior Consultant – Global Pricing and Market Access, Petauri Evidence) interviewed four regional experts:
 For Argentina: Eleonora Aiello (CEO at Ceibo Health Consulting)
 For Brazil: Alessandra Calabró (Independent expert in market access and government affairs)
 For Colombia: María Fernanda Escobar (Principal Advisor, InnovaSalud)
 For Mexico: Fernando del Río (Partner at InnovaSalud, GP at XB Ventures)
Together, they unpack the access landscape in their countries, sharing experience‑based insight to help global teams refine evidence plans and align global materials to local payer expectations.
Together, they explore:
Variation in healthcare systems, regulatory structures, and payer landscapes across LATAM
HTA landscape in key markets and the influence of bodies such as CONITEC in Brazil, IETS in Colombia, CENETEC in Mexico, and ANEFiTS in Argentina
Differences in evidence expectations, including clinical, economic, and real‑world data requirements
How global dossiers, value messages, and evidence packages can better support affiliates engaging with local payers
Opportunities and challenges for introducing Pharma and Medtech innovations into LATAM markets
Future policy, regulatory, and reimbursement developments to monitor across the region
This episode was first broadcast as a live webinar on Thursday 19th March 2026. For more information about this webinar see: https://petauri.com/insights/latam-market-access-unlocked/

For support with market access strategy and global launch, please reach out to [email protected].
Subscribe to our newsletter to hear more  news, insights and events from Petauri Evidence

Send us Fan Mail
What does the evolving NHS landscape look like through the eyes of a Chief Pharmacist, and how are integrated care system (ICS) pharmacy teams responding?
In this Petauri Evidence NHS Whispers session, we put your questions to Yousaf Ahmad (Chief Pharmacist and Director of Medicines Optimisation, Frimley ICS), as he shares how he and his colleagues are responding to the changing NHS environment. From system pressures and financial constraints to prescribing priorities and service redesign, Yousaf explored how ICS pharmacy teams are adapting, and what this means for industry partners.
This episode was first broadcast as live webinar on: Friday 24th October 2025.
Learn more about this episode at https://petauri.com/insights/evolving-nhs-ics-chief-pharmacists-perspective/
Subscribe to our newsletter to hear more  news, insights and events from Petauri Evidence

Send us Fan Mail
What makes Switzerland a compelling first-launch market for Pharma? How does its healthcare system compare to other European countries? What do manufacturers need to know about reimbursement, pricing, and evidence requirements? How might the evolving Joint Clinical Assessment (JCA) landscape influence launch sequencing?

This episode explores Switzerland’s potential as an early launch market.

In this session, Louise Maddison (Senior Consultant – Global Pricing and Market Access, Petauri Evidence) interviewed Dr Elisabeth Brock (Independent expert in market access in Switzerland), who has extensive experience in Swiss healthcare, including regulatory and payer engagement, dossier preparation for the Swiss Specialities List (SL), and strategic launch planning.

Together, we explored what global market access teams need to know about launching in Switzerland – from regulatory routes and pricing frameworks to the nuances of payer expectations and evidence generation.

We discussed:
- What makes Switzerland attractive as a first-launch market
 - Key differences between Swiss and European Union (EU) market access pathways
 - How to prepare for inclusion on the SL and what “economically efficient pricing” really means
 - The role of cantonal (state) variation and decentralised healthcare in shaping access
 - How Swiss decisions may be influenced by the EU’s JCA
 - What global teams can learn from Swiss strategy to inform broader launch planning
This episode was first broadcast as a live webinar on Thursday 16th October 2025

Learn more at  https://petauri.com/insights/market-access-switzerland/
Subscribe to our newsletter to hear more  news, insights and events from Petauri Evidence

Send us Fan Mail
In this NHS Whispers live Q&A webinar, Katie Mulholland (Senior Consultant, UK Market Access, Petauri Evidence) speaks to:
 - Sarah Everest Ford (Programme Director, Health and Care Partnership)
 - Patrick McGee (Deputy Programme Director for Pathology, Lancashire & South Cumbria)
 - Prof. Phil Richardson (Former Dorset ICS System Commissioning Director; now Chief Innovation Officer, Petauri Evidence)

Together, they explore the implications of changing NHS structure and policy, and what this means for your market access, stakeholder engagement, and product innovation strategies.

This episode was first broadcast as a live webinar on 19th September 2025. Some to the topics discussed may evolve over time. This session was shaped by your questions. Key themes included:
 - Evolving NHS structures, policies, and practices – and what this means for industry
 - Strategic commissioning: where will it happen, and who will lead it?
- The 10 Year Plan and its implications for innovation and access
 - How industry can adapt to new engagement models and financial constraints
 - What the shift to integrated neighbourhoods means for product rollout and service design

Learn more at: https://petauri.com/insights/evolving-nhs-landscape-policy-to-practice/

For support with navigating the evolving NHS and launching new medicines and products in England, please email [email protected]. 

Subscribe to our newsletter to hear more  news, insights and events from Petauri Evidence